PARP inhibition — opportunities in pancreatic cancer

Nature Reviews Clinical Oncology, Published online: 22 July 2019; doi:10.1038/s41571-019-0257-6An urgent clinical need exists to improve the survival of patients with pancreatic cancer through biomarker-driven therapeutic strategies. Such approaches include the targeting of metastatic pancreatic cancer that harbours germline BRCA mutations with poly(ADP-ribose) polymerase inhibitors as maintenance therapy following platinum-based chemotherapy.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research